HPTN Publications
| 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
| 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
| 2001 | 2000 | 1999 | 1998 |
Chi BH, Wang L, Read JS, Sheriff M, Fiscus S, Brown ER, Taha TE, Valentine M, Goldenberg R. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024. AIDS. 2005;19(16):1857-64.
Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005;97(12):896-05.
Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E. Longitudinal patterns of methamphetamine, popper (Amyl Nitrite), and the cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health. 2005;82(1 Suppl 1):i62-i70.
Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J. Sensitivity and specificity of the ViroSeq® HIV-1 Genotyping System for detection of HIV-1 drug resistance mutations using an ABI PRISM® 3100 Genetic Analyzer. J Clin Micro. 2005;43(2):813-17 PMCID: 548107.
Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, Jackson JB. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr. 2005;39(5):593-97.
Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB. Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005;40(1):24-9.
Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192(1):30-6.
Eshleman SH, Hoover DR, Chen SH, Hudelson SH, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, and Taha T. Resistance after single dose nevirapine prophylaxis emerges in a high portion of Malawian newborns. AIDS. 2005;19(18):2167-68.
Eshleman SH, Hudelson S, Gupta A, Bollinger R, Divekar AD, Gangakhedkar RR, Kulkarni SS, Thakar MR, Paranjape RS, and Tripathy S. Limited evolution in the HIV-1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses. 2005;21(1):93-97.
Flys T, Marlowe N, Hackett J, Parkin N, Schumaker M, Holzmayer V, Hay P, and Eshleman SH. Analysis of PTAP duplications in the gag p6 region of subtype C HIV-1. AIDS Res Hum Retroviruses. 2005;21(8):739-41.
Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192(1):24-9.
Jones D, Parkin N, Hudelson SE, Guay LA, Musoke P, Mmiro F, Jackson JB, Eshleman SH. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine. AIDS Res Hum Retroviruses. 2005;21(14):319-24.
Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, Maldonado Y, Adeniyi Jones S, Mofenson L, Contag CH, Bassett M, Katzenstein DA. Breast-milk shedding of drug-resistant HIV-1 Subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005;192(7):1260-4.
Woodsong C, Karim QA. A model designed to enhance informed consent: experiences from the HIV prevention trials network. Am J Public Health. 2005;95(3):412-19.
